|
⚲
|
| Keyboard |
| Caligan Partners LP
✚
|
|
|---|---|
| CRD # | 289887 |
| SEC # | 801-113810 |
| CIK # | 0001727492 |
| AUM | 1,299.7 M (2026-05-29) |
| Employees | 5 (60% Investors, 0% Brokers) |
| Phone | 646-859-8204 |
| Address | 780 Third Avenue New York, NY 10017 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Liquidia Corp | 306.4 | ||
| Revolution Medicines Inc | 183.0 | ||
| Abivax Sa | 162.8 | ||
| Vaxcyte Inc | 119.7 | ||
| Xenon Pharmaceuticals Inc | 81.0 | ||
| Mineralys Therapeutics Inc | 75.1 | ||
| Exelixis Inc | 66.6 | ||
| CG Oncology Inc | 60.9 | ||
| BCTG Acquisition Corp | 50.4 | ||
| TYRA Biosciences Inc | 48.9 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Caligan Partners CV VII LP | 2024-03-28 | ||
| HF | Caligan Partners CV VI LP | [2024-03-28] | 14.6 M | 36.0 M |
| Filed 2024-05-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners CV IV LP | [2022-03-30] | 18.2 M | 175.6 M |
| Filed 2021-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners CV V LP | [2022-03-30] | 18.2 M | 9.6 M |
| Filed 2021-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners Master Fund LP | [2022-03-30] | 6.9 M | 812.0 M |
| Offered $6,946,060 · Filed 2025-08-15 (D/A) · Exemption 506(c) · Minimum $500,000 · Duration More than one year · Revenue $1,000,001 - $5,000,000 | ||||
| HF | Caligan Partners CV III LP | [2021-03-25] | 33.9 M | 42.2 M |
| Filed 2020-12-09 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners CV II LP | 2020-03-26 | 39.9 M | |
| HF | Caligan Partners CV I LP | [2019-02-04] | 19.0 M | 23.8 M |
| Filed 2019-01-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 1,299.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 1,299.7 |
| By Discretionary | ||
| Discretionary | 8 | 1,299.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 1,299.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 666.7 | |
| United States Persons | 633.0 | |
| Total | 8 | 1,299.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Caligan Partners LP | Promoter | 6 | 2 | |
| Caligan Partners CV VI GP LLC | Executive Officer | 1 | 1 | |
| Samuel Merksamer | Executive Officer | 1 | 1 | |
| Caligan Partners CV IV GP LLC | Executive Officer | 1 | 1 | |
| Caligan Partners CV IV LP | Promoter | 1 | 1 | |
| Caligan Partners CV III GP LLC | Executive Officer | 1 | 1 | |
| Caligan Partners CV GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001727492] | |
| 3 | [0001727492] | |
| 4 | [0001727492] | |
| SC 13D | [0001727492] | |
| SC 13G | [0001727492] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund |
| LEI | 549300FWK7CGQ83RTY05 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Exelixis Inc EXEL
Common Stock
|
2025-11-25 | Buy | 27,532 | $43.12 | 1,187,180 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2025-06-17 | Grant | 18,396 | $0.00 | |
|
Exelixis Inc EXEL
Option (right to buy) · derivative
|
2025-05-29 | Grant | 21,464 | $0.00 | |
|
Alimera Sciences Inc ALIM
"Common Stock, par value $0.01 per share (""Common Stock"")"
|
2024-09-16 | Other | 16,835,154 | ||
|
Alimera Sciences Inc ALIM
Warrants · derivative
|
2024-09-16 | Other | 800,000 | ||
|
Alimera Sciences Inc ALIM
Notional Derivative Agreements (obligation to buy) · derivative
|
2024-09-16 | Other | 1 | ||
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2024-09-12 | Grant | 1,123,595 | $8.90 | 9,999,996 |
|
Liquidia Corp LQDA
Common Stock
|
2024-08-30 | Sell | 150,000 | $9.51 | 1,426,500 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2024-08-30 | Other | 3,440,948 | ||
|
Liquidia Corp LQDA
Common Stock
|
2024-08-30 | Buy | 150,000 | $9.51 | 1,426,500 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2024-06-20 | Grant | 20,359 | $0.00 | |
|
Exelixis Inc EXEL
Option (right to buy) · derivative
|
2024-05-31 | Grant | 42,767 | $0.00 | |
|
Exelixis Inc EXEL
Common Stock
|
2024-05-30 | Buy | 225,000 | $20.76 | 4,671,000 |
|
Exelixis Inc EXEL
Common Stock
|
2024-05-28 | Buy | 200,000 | $20.32 | 4,064,000 |
|
Exelixis Inc EXEL
Common Stock
|
2024-02-21 | Buy | 190,000 | $20.70 | 3,933,000 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2023-12-14 | Buy | 1,117,318 | $7.16 | 7,999,997 |
|
Exelixis Inc EXEL
Common Stock
|
2023-11-27 | Buy | 120,409 | $21.61 | 2,602,038 |
|
Exelixis Inc EXEL
Common Stock
|
2023-11-27 | Sell | 120,409 | $21.61 | 2,602,038 |
|
Alimera Sciences Inc ALIM
Common Stock
|
2023-09-14 | Buy | 579,000 | $3.39 | 1,962,810 |
|
Alimera Sciences Inc ALIM
Notional Derivative Agreements (obligation to buy) · derivative
|
2023-09-14 | Other | 1 | ||
| showing 20 of 56 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Weatherbie Capital LLC
✚
|
MA | 1,343.1 M |
|
Coury Firm Asset Management LLC
✚
|
PA | 1,324.8 M |
|
Paragon Capital Management
✚
|
CO | 1,316.2 M |
|
Savoie Capital LLC
✚
|
IL | 1,315.0 M |
|
Synergy Asset Management LLC
✚
|
WA | 1,299.4 M |
|
New Legacy Group LLC
✚
|
NY | 1,283.7 M |
|
Private Capital Advisors Inc
✚
|
CT | 1,281.8 M |
|
L2 Asset Management LLC
✚
|
1,270.8 M | |
|
Zadig Asset Management Sa
✚
|
1,252.2 M | |
|
Arbiter Partners Capital Management LLC
✚
|
NY | 1,250.7 M |